About Us
TWi USA
USA Team
Our Products
For Customers
Authorized Distributors
TWi USA State Licenses
Return Goods Policy
Customer Service Contacts
For Patients
Adverse Event Reporting, Product Complaints & Medical Information(FOr USA Only)
Contact Us
buPROPion Hydrochloride Extended-Release Tablets (XL)
Cyclobenzaprine Hydrochloride Extended-Release Capsules
Dexlansoprazole Delayed-Release Capsules
Diltiazem Hydrochloride Extended-Release Capsules
Dimethyl Fumarate Delayed-Release Capsules
Donepezil tablets
Fenofibric Acid Delayed-Release Capsules
Guanfacine Hydrochloride Extended-Release Tablets
Hydroquinone Cream
MegestrolAcetate Oral Suspension
Metformin Hydrochloride Extended Release Tablets
Metoprolol Succinate Extended-Release Tablets
Mycophenolic Acid DR Tablets
Nifedipine Extended-Release tablets
Paclitaxel Protein-Bound Particles for Injectable Suspension - (Albumin-Bound)
Propafenone Hydrochloride Extended-Release Capsules, USP
Sevelamer Carbonate Tablets
Terbutaline Sulfate tablets
Testosterone Gel, 1.62% CIII
Home > Products > For the United States
Fenofibric Acid Delayed-Release Capsules
Route
Oral
Dosage form
Capsules
Strength
45mg and 135mg
Rx/OTC
Rx
Indication
Adjunctive therapy to diet to reduce triglycerides (TG) in patients with severe hypertriglyceridemia.
TE Rating
AB
Reference Listed Drug
Triplix®
ANDA#
210469
Strength
Form
Product Description
Imprint
Image
How Supplied
NDC Number
HDMA
Sheets
PI
SDS
45mg
Delayed-release capsules
45 mg have a burnt umber opaque cap imprinted with “TWi T109” in white ink and a mustard opaque body imprinted with “45mg” in black ink.
“TWi T109” in white ink and a mustard opaque body imprinted with “45mg” in black ink.
Bottle of 90
24979-109-07
135mg
Delayed-release capsules
135 mg have a blue opaque cap imprinted with “TWi T112” in white ink and a yellow opaque body imprinted with “135mg” in black ink.
“TWi T112” in white ink and a yellow opaque body imprinted with “135mg” in black ink.
Bottle of 90
24979-112-07
Back
Top